 SEATTLE, WA and VANCOUVER, BC ACCESSWIRE August 12, 2021 Achieve Life Sciences, Inc. Nasdaq:ACHV, a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Events Highlights Announced completion of enrollment in the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3.0 mg cytisinicline dosed 3 times daily TID compared to placebo in adult smokers Awarded grant from the National Institute on Drug Abuse NIDA of the National Institutes of Health NIH for the evaluation of cytisinicline in cessation of nicotine e-cigarette use Issued two new patents from the United States Patent and Trademark Office covering the novel 3.0 mg TID cytisinicline dosing regimen Closed financing with gross proceeds of 23 million, prior to deducting underwriting discounts and offering expenses In the second quarter, we continued to demonstrate our commitment to stakeholders by delivering on key milestones that advance our clinical program, and ultimately, cytisiniclines potential ability to help millions of people who struggle with nicotine addiction to live healthier lives, commented John Bencich, Chief Executive Officer of Achieve. 